237 related articles for article (PubMed ID: 12535239)
1. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States.
Caprini JA; Botteman MF; Stephens JM; Nadipelli V; Ewing MM; Brandt S; Pashos CL; Cohen AT
Value Health; 2003; 6(1):59-74. PubMed ID: 12535239
[TBL] [Abstract][Full Text] [Related]
2. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
[TBL] [Abstract][Full Text] [Related]
4. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event.
Mahan CE; Holdsworth MT; Welch SM; Borrego M; Spyropoulos AC
Thromb Haemost; 2011 Sep; 106(3):405-15. PubMed ID: 21833446
[TBL] [Abstract][Full Text] [Related]
5. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
7. A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil.
Ramacciotti E; Gomes M; de Aguiar ET; Caiafa JS; de Moura LK; Araújo GR; Truzzi A; Dietrich-Neto F;
Thromb Res; 2006; 118(6):699-704. PubMed ID: 16417913
[TBL] [Abstract][Full Text] [Related]
8. Economic consequences of venous thromboembolism following major orthopedic surgery.
Oster G; Ollendorf DA; Vera-Llonch M; Hagiwara M; Berger A; Edelsberg J
Ann Pharmacother; 2004 Mar; 38(3):377-82. PubMed ID: 14742829
[TBL] [Abstract][Full Text] [Related]
9. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and cost of deep venous thrombosis among patients with cancer.
Elting LS; Escalante CP; Cooksley C; Avritscher EB; Kurtin D; Hamblin L; Khosla SG; Rivera E
Arch Intern Med; 2004 Aug 9-23; 164(15):1653-61. PubMed ID: 15302635
[TBL] [Abstract][Full Text] [Related]
11. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.
Caro JJ; Getsios D; Caro I; O'Brien JA
Pharmacoeconomics; 2002; 20(9):593-602. PubMed ID: 12141887
[TBL] [Abstract][Full Text] [Related]
14. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
15. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
16. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery.
Casele H; Grobman WA
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):535-40. PubMed ID: 16946212
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
19. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of screening for deep vein thrombosis by ultrasound at admission to stroke rehabilitation.
Wilson RD; Murray PK
Arch Phys Med Rehabil; 2005 Oct; 86(10):1941-8. PubMed ID: 16213235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
